PRSS1 genotype is associated with prognosis in patients with pancreatic ductal adenocarcinoma

HUASHENG WU1*, FADIAN DING2*, XIJUN CHEN2, SHAOQIN CHEN3, ZHEN SHI2, QICAI LIU4, ZHENHUA ZHENG1 and YOUTING CHEN2

1Department of Hepatobiliary Surgery, San Ming First Hospital, Sanming, Fujian 365000; 2Department of Hepatobiliary Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350001; 3Department of Critical Care Medicine, Xiamen Cardiovascular Hospital Xiamen University, Xiamen, Fujian 361000; 4Department of Laboratory Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350001, P.R. China

Abstract. The prognostic value of the genotype of the PRSS1 gene in patients with pancreatic ductal adenocarcinoma (PDAC) remains poorly understood. The aim of the present study was to evaluate the association between the PRSS1 genotype and clinicopathological characteristics of patients with PDAC, as well as to explore the prognostic significance of the PRSS1 genotype in patients with PDAC. A total of 124 patients with PDAC patients were included in the current study and the PRSS1 genotype of the enrolled patients was determined by the polymerase chain reaction. Associations between the PRSS1 genotype and clinicopathological characteristics were subsequently analyzed using the Chi-square test. The impact of the PRSS1 genotype on patient prognosis was assessed using the Kaplan-Meier method, and predictive factors of overall survival (OS) time were analyzed by Cox regression. A total of 56 patients with PDAC (45.16%) had the T/C PRSS1 genotype, which was associated with large tumor sizes (P=0.027) and higher tumor node metastasis (TNM) stages (P=0.041). Following a median follow-up of 19 months, the T/C genotype of PRSS1 was associated with a shorter OS time (P=0.037) compared with the C/C or T/T PRSS1 genotypes. Univariate and multivariate analyses revealed that PRSS1 genotype was identified to be an independent prognostic factor for the OS time of patients with PDAC. The results obtained in the current study suggested that the PRSS1 genotype, as well as factors such as the serum level of carbohydrate antigen 19-9 and the TNM stage, may act as independent prognostic factors for the OS time of patients with PDAC.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and has a 5-year survival rate of 6% was reported in year 2011 worldwide (1). Although advances have been made in the prevention of PDAC as well as in surgical approaches and adjuvant therapy, the mortality rates in patients with PDAC remain high (2,3). Several risk factors such as smoking (4), diabetes (5) and hereditary pancreatitis (6) have been identified. However, tissue biomarkers or gene signatures for the prognosis prediction of PDAC have not been well established (7). The identification of a reliable prognostic genetic determinant in PDAC is an area of ongoing research and may aid in individualized risk assessment and treatment decision-making. Furthermore, biomarkers might present novel therapeutic targets for the treatment of PDAC.

The inflammatory process is a key mediator of pancreatic cancer development and progression, and patients with chronic pancreatitis have an increased risk of developing pancreatic cancer (8-10). Trypsin-1, the main trypsinogen secreted by the pancreas and encoded by the serine protease 1 gene (PRSS1), has attracted attention in the field of PDAC research (11). Previous studies revealed that mutations in PRSS1 are associated with autoimmune (12) and chronic pancreatitis (13). Progressive mutation accumulation and clonal expansion, however, are required for the development of invasive PDAC (11). Mutations in the PRSS1 gene have been reported to be associated with an increased incidence of PDAC (10,14-16). The -409 C/T PRSS1 genotype has been found to protect against the development of pancreatic cancer in the Han Chinese population (17); however, the prognostic value of the aforementioned PRSS1 genotype in patients with PDAC remains poorly understood.

The aim of the current study was to investigate the association of the -409 C/T PRSS1 genotype with the clinicopathological characteristics and prognosis of patients with PDAC.

Correspondence to: Dr Youting Chen, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Fujian Medical University, 20 Chazhong Road, Fuzhou, Fujian 350001, P.R. China
E-mail: cytdf110@163.com

Dr Zhenhua Zheng, Department of Hepatobiliary Surgery, San Ming First Hospital, 29 Liedong Road, Sanming, Fuzhou, Fujian 365000, P.R. China
E-mail: smdyyzzh@163.com

*Contributed equally

Key words: serine protease 1, pancreatic cancer, prognosis
Materials and methods

Patient recruitment. Patients with PDAC from The First Affiliated Hospital of Fujian Medical University (Fuzhou, China) were enrolled between 2015 and 2017. The inclusion criteria were as follows: i) Patients with pathologically confirmed PDAC diagnosis; ii) patients who had received radical resection; and iii) patients who had not received any preoperative therapy (including radiotherapy, chemotherapy or targeted therapy). Patients with any comorbid or previous malignancies were excluded from the analysis. A total of 124 patients were eligible for inclusion in the current study, including 76 males and 48 females, with a median age of 60 years (range, 28-86 years).

The present study was performed in accordance with the ethical principles described in the Declaration of Helsinki and was approved by the Ethics and Research Committee of The First Affiliated Hospital of Fujian Medical University. Written informed consent was obtained from all patients.

Genotype analysis. Peripheral blood samples were collected from the peripheral vein. Following anticogulation with EDTA and centrifugation in 1,509 x g at 4˚C for 5 min, genomic DNA was extracted from each patient using a TIANamp Blood DNA kit (Tiangen Biotech Co., Ltd.), and was stored at -20˚C. Following the manufacturer's instructions, the full-length PRSS1 gene was amplified, and following purification, sequencing was performed and analyzed by Sangon Biotech Co., Ltd. The 50 µl reaction mixture used to generate the fragments contained 200 ng genomic DNA, 10 mmol/l Tris-hydrochloric acid (pH 9.0), 50 mmol/l potassium chloride, 0.1% triton, 2 mmol/l magnesium chloride, 0.25 mmol/l deoxy-nucleotide mix, 100 ng upstream primer, 100 ng downstream primer and 3.0 units of Taq DNA-polymerase (Sangon Biotech Co., Ltd. The 50 µl reaction mixture used to generate the fragments contained 200 ng genomic DNA, 10 mmol/l Tris-hydrochloric acid (pH 9.0), 50 mmol/l potassium chloride, 0.1% triton, 2 mmol/l magnesium chloride, 0.25 mmol/l deoxy-nucleotide mix, 100 ng upstream primer, 100 ng downstream primer and 3.0 units of Taq DNA-polymerase (Sangon Biotech Co., Ltd. The thermocycling conditions included an initial denaturing step at 95˚C for 5 min, followed by 30 cycles at 95˚C for 30 sec, 55˚C for 30 sec and 72˚C for 1 min, followed by a final extension step at 72˚C for 10 min. PCR products were subsequently run on an 1% agarose gel in 1X TAE buffer and purified by a MinElute Gel Extraction kit (Qiagen GmbH). Following the manufacturer's instructions, a PCR was used to determine the PRSS1 genotype in the enrolled patients. The results revealed that multiple loci contained one of three genotypes: C/C, C/T, T/T (Fig. 1), which is similar to results that have been previously reported (18,19). Moreover, 58 patients with PDAC (43.75%) had the T/C genotype (Table I), which was regarded as a mutation.

Associations between the PRSS1 genotype and clinicopathological characteristics. As shown in Table I, the T/C PRSS1 genotype was associated with larger tumor sizes (P=0.027), higher tumor-node-metastasis (TNM) stages (P=0.041) and higher levels of serum carcinoembryonic antigen (CEA) (P=0.038) compared with the C/C or T/T PRSS1 genotypes. However, no associations between the T/C PRSS1 genotype and age, sex, tumor location, serum carbohydrate antigen (CA) 19-9 and 12-5 levels, perineural invasion or lymphovascular invasion were observed (all P>0.05).

A multivariate analysis using the Cox regression model was subsequently performed, and the results revealed that the serum CA19-9 level [hazard ratio (HR)=1.001; P=0.001], TNM stage III (HR=1.005; P=0.001), and PRSS1 genotype (P=0.002) were significantly associated with the OS time of patients with PDAC (Table II).

A multivariate analysis using the Cox regression model was subsequently performed, and the results revealed that the serum CA19-9 level [hazard ratio (HR)=1.001; P=0.001], TNM stage III (HR=3.090; P=0.041), and PRSS1 genotype (HR=2.196; P=0.002) were independent predictors of the OS time in patients with PDAC (Table III).

Discussion

The current study revealed that the T/C PRSS1 genotype was statistically associated with larger tumor size and higher TNM stage compared with other genotypes. To the best of the authors' knowledge, the present study was the first to demonstrate that the T/C PRSS1 genotype was associated with poor OS, and that the aforementioned genotype may serve as an independent prognostic factor of OS in patients with PDAC, together with factors including serum CA19-9 level and TNM stage.

Previous studies revealed that the processes of genotype accumulation and clonal expansion are required for the development of invasive PDAC (11,16,20). Many efforts have been made to identify gene mutations associated with pancreatic cancer, including mutL homolog 1 and PMS1 homolog 1, mismatch repair system component (21), and BRCA1/2 DNA repair (22). Increasing numbers of studies have demonstrated that mutations in the PRSS1 gene are associated with an
increased incidence of PDAC (10,14–16). Furthermore, the
-409 C/T PRSS1 genotype was found to exert a protective
effective against pancreatic cancer in the Han Chinese popu-
lation (17). PRSS1 encodes trypsin-1, the main trypsinogen
enzyme secreted by the pancreas. PRSS1 mutations have
been associated with increased trypsin-1 serum levels as
well as the trypsin and α1-antitrypsin imbalance observed in
patients with pancreatic cancer, which may alter the pancreatic
microenvironment and increase immunological escape and
clonal proliferation of pancreatic cancer cells (19). However,
the clinicopathological and prognostic significance of PRSS1
mutations in patients with PDAC remains unclear.
PRSS1 mutations have been previously shown to be associated
with autoimmune (12) and chronic pancreatitis (13). Additionally,
the mean serum trypsin level was increased in patients with
pancreatic cancer compared with healthy controls (19). While
the PRSS1 gene is not currently considered to be an oncogene,
tumor-suppressor gene or genome-maintenance gene, PRSS1
genotypes were strongly correlated with the trypsin and α1-antitrypsin imbalance in patients with pancreatic cancer (13).

Traditional prognostic factors, including serum CA19-9
level and TNM stage, were identified as independent prog-
nostic factors of OS in patients with PDAC in the current study,
similarly to previously published studies (7,23). In the current
study, the T/C PRSS1 genotype indicated a poor prognosis and
a shorter OS time in patients with PDAC, as demonstrated by
the Kaplan-Meier method. Furthermore, associations between
the PRSS1 genotype and clinicopathological parameters such
as large tumor size and higher TNM stage were identified in
the current study, suggesting that the PRSS1 genotype may
be involved in the progression and aggressiveness of pancreatic
cancer. Moreover, by using univariate and Cox regression
analysis, the results obtained in the current study demonstrated
that the PRSS1 genotype was an independent prognostic factor
of OS in patients with PDAC. The PRSS1 genotype may aid the
selection of treatment plans and the identification of patients
who may benefit from additional adjuvant therapy.

The current study had a number of limitations. Firstly,
the present study was a single-centre retrospective study.
Secondly, a limited sample size was included in the current
study. Thirdly, patients with unresectable PDAC were not
included in the current study due to insufficient data. Finally,
all the patients enrolled in the current study were of Chinese
descent, therefore the association between the mutation status
of PRSS1 and prognosis of patients of different ethnicities was
not investigated. Nevertheless, the current study contributed
to the understanding of the association between the PRSS1
genotype and prognosis of patients with PDAC.

In conclusion, the current study demonstrated that the
T/C PRSS1 genotype was associated with large tumor
size, higher TNM stage and poor OS compared with other
genotypes. The PRSS1 genotype, together with other factors

Figure 1. Representative DNA sequencing analysis for rs181626272. Gene mutation sites of the serine protease 1 gene genotypes (A) T/T, (B) C/C and (C) C/T. The red arrows refer to the gene mutation sites.
Table I. Prognostic impact of \textit{PRSS1} genotype on the prognosis of patients with pancreatic ductal adenocarcinoma.

| Variable                              | \textit{PRSS1} genotype |
|---------------------------------------|-------------------------|
|                                       | T/C                     | T/T and C/C               | P-value   |
| Age, years (mean ± SD)                | 61.5±12.7               | 59.7±10.3                 | 0.253     |
| Sex, n (%)                            |                         |                          | 0.534     |
| Male                                  | 36 (64.3)               | 40 (58.8)                 |           |
| Female                                | 20 (35.7)               | 28 (41.2)                 |           |
| Tumor size, cm (mean ± SD)            | 3.9±2.6                 | 3.2±1.5                   | 0.027     |
| Tumor location, n (%)                 |                         |                          | 0.688     |
| Head                                  | 41 (73.2)               | 53 (77.9)                 |           |
| Body and tail                         | 15 (26.8)               | 15 (22.1)                 |           |
| CEA, ng/ml (mean ± SD)                | 7.7±15.1                | 15.9±48.7                 | 0.038     |
| CA19-9, U/ml (mean ± SD)              | 291.6±375.9             | 302.2±361.5               | 0.717     |
| CA125, U/ml (mean ± SD)               | 50.1±89.3               | 45.7±78.7                 | 0.460     |
| TNM stage, n (%)                      |                         |                          | 0.041     |
| I                                     | 11 (19.6)               | 19 (27.9)                 |           |
| II                                    | 13 (23.2)               | 27 (39.7)                 |           |
| III                                   | 27 (48.2)               | 20 (29.4)                 |           |
| IV                                    | 5 (8.9)                 | 2 (2.9)                   |           |
| Perineural invasion, n (%)            |                         |                          | 0.874     |
| Yes                                   | 19 (33.9)               | 24 (35.3)                 |           |
| No                                    | 37 (66.1)               | 44 (64.7)                 |           |
| Vascular invasion, n (%)              |                         |                          | 0.442     |
| Yes                                   | 43 (76.8)               | 56 (82.4)                 |           |
| No                                    | 13 (23.2)               | 12 (17.6)                 |           |

\textit{PRSS1}, serine protease 1; TNM, tumor-node-metastasis; CEA, carcinoembryonic antigen; CA, carbohydrate antigen.

Table II. Univariate analysis of factors affecting the overall survival time in patients with pancreatic ductal adenocarcinoma.

| Variable                              | HR          | 95% CI           | P-value |
|---------------------------------------|-------------|------------------|---------|
| Sex (male vs. female)                 | 0.785       | 0.510-1.208      | 0.271   |
| Age                                   | 1.016       | 0.996-1.036      | 0.113   |
| Surgery type (Whipple surgery vs. pancreatectomy) | 1.626       | 1.042-2.537      | 0.032   |
| Resection margin (yes vs. no)         | 1.049       | 0.476-2.315      | 0.905   |
| Tumor size                            | 1.155       | 1.038-1.285      | 0.008   |
| Serum CA19-9 level                    | 1.001       | 1.000-1.002      | 0.001   |
| Serum CEA level                       | 1.007       | 1.001-1.014      | 0.034   |
| Serum CA125 level                     | 1.001       | 0.999-1.004      | 0.194   |
| TNM stage                             |             |                  |         |
| I                                     | Reference value |                  |         |
| II vs. I                              | 1.691       | 0.931-3.072      | 0.085   |
| III vs. I                             | 2.257       | 1.272-4.005      | 0.005   |
| IV vs. I                              | 5.320       | 2.186-12.947     | <0.001  |
| Perineural invasion (yes vs. no)      | 1.303       | 0.841-2.020      | 0.237   |
| Vascular invasion (yes vs. no)        | 1.487       | 0.921-2.398      | 0.104   |
| \textit{PRSS1} genotype (T/C vs. C/C or T/T) | 1.961       | 1.293-2.973      | 0.002   |

HR, hazard ratio; CEA, carcinoembryonic antigen; CA, carbohydrate antigen. \textit{PRSS1}, serine protease 1 gene.
including serum CA19-9 level and TNM stage, may therefore be used as an independent prognostic factor of OS in patients with PADC.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### Table III. Multivariate analysis of factors affecting the overall survival time in patients with pancreatic ductal adenocarcinoma.

| Variable                                      | Regression coefficient | SE   | HR   | 95% CI       | P-value |
|-----------------------------------------------|------------------------|------|------|--------------|---------|
| Surgery type (Whipple surgery vs. pancreatectomy) | -0.009                 | 0.274| 0.991| 0.579-1.695  | 0.973   |
| Tumor size                                    | 0.081                  | 0.067| 1.085| 0.952-1.236  | 0.223   |
| Serum CA19-9 level                            | 0.001                  | <0.001| 1.001| 1.000-1.002  | 0.001   |
| Serum CEA level                               | 0.006                  | 0.005| 1.006| 0.996-1.016  | 0.230   |
| TNM stage                                     |                        |      |      |              |         |
| I Reference value                             |                        |      |      |              | 0.110   |
| II vs. I                                      | 0.613                  | 0.345| 1.847| 0.938-3.634  | 0.076   |
| III vs. I                                     | 0.731                  | 0.339| 2.078| 1.068-4.041  | 0.031   |
| IV vs. I                                      | 1.128                  | 0.551| 3.090| 1.049-9.104  | 0.041   |
| PRSS1 genotype (T/C vs. C/C or T/T)           | 0.786                  | 0.249| 2.196| 1.347-3.580  | 0.002   |

SE, standard error; HR, hazard ratio; CEA, carcinoembryonic antigen; CA, carbohydrate antigen, PRSS1, serine protease 1 gene.

Authors’ contributions

HW, ZZ and YC conceived and designed the study. FD and XC acquired data. HW, SC, ZS and QL analysed the data. HW, ZZ and YC interpreted, drafted and revised the manuscript. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate

The present study was approved by the Ethics and Research Committee of The First Affiliated Hospital of Fujian Medical University (approval no. 2018-053). Written informed consent was obtained from all patients.

Patient consent for publication

Not applicable.

Figure 2. Overall survival time of patients with pancreatic ductal adenocarcinoma grouped by PRSS1 genotype. There was no significant difference between the T/T and C/C PRSS1 genotype (P=0.761). PRSS1, serine protease 1 gene.
Competing interests

The authors declare that they have no competing interests.

References

1. Ryan D, Hong T and Bardeesy N: Pancreatic adenocarcinoma. N Engl J Med 371: 2140-2141, 2014.
2. Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, et al: Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: A phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388: 248-257, 2016.
3. Picozzi VJ, Oh SY, Edwards A, Mandelson MT, Dorer R, Rocha FG, Alseidi A, Biehl T, Traverso LW, Helton WS, et al: Five-year actual overall survival in resected pancreatic cancer: A contemporary single-institution experience from a multidisciplinary perspective. Ann Surg Oncol 24: 1722-1730, 2017.
4. Liu QC, Zhuang ZH, Zeng K, Liu A and Gao F: The -409 C/T genotype of PRSS1 protects against pancreatic cancer in the Han Chinese population. Dig Dis Sci 57: 573-579, 2012.
5. Winter JM, Yeo CJ and Brody JR: Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol 107: 15-22, 2013.
6. Hausmann S, Kong B, Michalski C, Erkan M and Friess H: The role of inflammation in pancreatic cancer. Adv Exp Med Biol 816: 129-151, 2014.
7. Pinho A, Chantrill L and Rooman I: Chronic pancreatitis: A path to pancreatic cancer. Cancer Lett 345: 203-209, 2014.
8. Weiss F: Pancreatic cancer risk in hereditary pancreatitis. Front Physiol 5: 70, 2014.
9. Whitcomb DC: Genetic risk factors for pancreatic disorders. Gastroenterology 144: 1292-1302, 2013.
10. Gao F, Li YM, Hong GL, Xu ZF, Liu QC, He QL, Lin LQ and Weng SH: PRSS1_p.Leu81Met mutation results in autoimmune pancreatitis. World J Gastroenterol 19: 3332-3338, 2013.
11. Gao F, Liu QC, Zhang S, Zhuang ZH, Lin CZ and Lin XH: PRSS1 intron mutations in patients with pancreatic cancer and chronic pancreatitis. Mol Med Rep 5: 449-451, 2012.
12. Hengstler JG, Bauer A, Wolf HK, Bulitta CJ, Tanner B, Oesch F, Gebhard S and Boettger T: Mutation analysis of the cationic trypsinogen gene in patients with pancreatic cancer. Anticancer Res 20: 2967-2974, 2000.
13. Rebours V, Bouton-Ruault M, Schnee M, Férec C, Maire F, Hammel P, Ruszniewski P and Lévy P: Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: A national exhaustive series. Am J Gastroenterol 103: 111-119, 2008.
14. Chen J and Férec C: Chronic pancreatitis: Genetics and pathogenesis. Annu Rev Genomics Hum Genet 10: 63-87, 2009.
15. Liu Q, Lin X, Liu J, Liu A and Gao F: The -409 C/T genotype of PRSS1 protects against pancreatic cancer in the Han Chinese population. Dig Dis Sci 57: 573-579, 2012.
16. Yi Q, Dong F, Lin L, Liu Q, Chen S, Gao F and He Q: PRSS1 mutations and the proteinase/antiproteinase imbalance in the pathogenesis of pancreatic cancer. Tumour Biol 37: 5805-5810, 2016.
17. Campa D, Pastore M, Capurso G, Hackert T, Di Leo M, Izbicki JR, Khaw KT, Gioffreda D, Kupcinets J, Pasquali C, et al: Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANCreatic Disease ReseArch (PANDoRA) consortium investigation. Int J Cancer 142: 290-296, 2018.
18. Gargiulo S, Torrini M, Ollila S, Nasti S, Pastorino L, Casano R, Bonelli L, Battistuzzi L, Mastracci L, Bruno W, et al: Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome. Fam Cancer 8: 547-553, 2009.
19. Fogelman D, Wolf R, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F and Abbruzzese J: Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res 31: 1417-1420, 2011.
20. Berger AC, Garcia M Jr, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB III, MacDonald J and Willett CG: Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: A prospective validation by RTOG 9704. J Clin Oncol 26: 5918-5922, 2008.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.